Introduction
Multiple myeloma (MM), the bone marrow (BM)-resident plasma cell (PC) neoplasm, is the second most common hematologic malignancy after Non-Hodgkin's lymphoma 1 . Although new therapies have improved survival, MM remains almost uniformly fatal and only curable in a small fraction of patients 2, 3 . Initially, patients are responsive to therapy and experience remission; however, relapses result in MM cells that are progressively resistant to therapy 3, 4 . Thus, understanding and overcoming resistance mechanisms may lead to development of new therapeutic approaches.
Chemotherapies such as the DNA alkylator melphalan and the proteasome inhibitor bortezomib were developed because of their direct apoptotic effects on MM cells 5, 6 . However, these agents, thalidomide, and thalidomide derivatives also target the BM microenvironment-pointing to the key role that stroma plays in myeloma survival [6] [7] [8] .
Moreover primary MM culture in vitro requires stroma, indicating that the BM niche provides essential pro-survival signals [9] [10] [11] . Thus, identifying key interactions between MM and the microenvironment is essential for understanding and overcoming therapeutic resistance mechanisms.
Broadly, MM-stromal interactions fall into two categories. The first consists of soluble pro-survival factors induced from stromal niche cells upon MM interaction, and include IL-6 12, 13 , indolamine-2, 3-dioxygenase (IDO) 14 , APRIL and BAFF [14] [15] [16] . The second category consists of contact-dependent interactions between MM cells and extracellular matrix 17, 18 or stromal cells 14, 19, 20 . Perhaps best characterized are integrindependent cell-adhesion mediated drug resistance (CAM-DR) 17, 21 and Notch signaling 22 . Both interactions halt cell cycle, regulate apoptotic molecules, and induce
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Expression of receptors that support MM survival would be predicted to correlate with worse prognosis or progression, consistent with a pro-survival role under treatment pressure. One such molecule is CD28, best characterized as the prototypic T cell costimulatory receptor. CD28 activation together with "signal 1" through the T cell receptor enhances function and survival 23, 24 . Although expressed on PC and MM cells 25 , CD28 function in the B cell lineage has been largely unexplored. We have reported that CD28 signaling is critical for murine BMPC survival and durable antibody titers, demonstrating CD28 is necessary for normal PC biology 26 . We also observed that CD28 activation in vitro protects MM cells from chemotherapy-induced death 20 . CD28's role as a pro-survival receptor for MM is consistent with the observation that CD28 is overexpressed on 26.5% of primary MM cells at diagnosis, 59% in medullary relapse, 93% in extramedullary relapse, and 100% of cell lines 27 . Moreover, CD28 overexpression is prognostically correlated with worse outcomes following high-dose chemotherapy [28] [29] [30] . Many CD28 + MM cells also co-express CD86 27 , one of CD28's ligands. CD86 expression has been separately found to be a poor prognostic indicator 31 , raising the possibility that MM utilizes CD28:CD86 cis interactions to deliver a pro-survival signal. Collectively, these data suggest CD28 supports survival, allowing for disease progression despite treatment. 24 , and we and others have found that macrophages and DC are pro-survival components of the MM niche 14, 19, 20 . We have previously shown that MM:DC co-culture transduces a pro-survival signal directly to MM cells and "backsignals" through CD80/CD86 on DCs to induce DC production of IL-6
and IDO. We hypothesize that blocking CD28 interactions in vivo would inhibit MMintrinsic pro-survival signals and stromal induction of a "soluble" prosurvival/immunosuppressive microenvironment, doubly sensitizing MM to chemotherapy.
Currently, the CD28 downstream components in myeloma cells are poorly characterized. However, CD28 signaling in T cells is more clearly delineated, and involves the phosphatidyl-inositol 3-kinase (PI3K)/Akt pathway 32, 33 . Similar to T cells, we have reported that CD28 activation in MM cells induces PI3K signaling-leading us to hypothesize that CD28 PI3K Akt signaling may mediate MM apoptotic resistance 20 .
This would be consistent with the general role PI3K/Akt plays in MM biology, where it mediates survival and proliferation 34, 35 . Based on the predictions of this hypothesis, we examined the effects of CD28 inhibition on MM survival in vitro and in vivo, and characterized downstream molecules in this pathway. 
Western blots
Western blot analysis was performed as previously described 20 . Briefly, cells were lysed using RIPA buffer, protein was quantitated, separated using 10-12% SDS-PAGE gel, electroblotted to nitrocellulose and probed with antibodies specific for Bim, total FoxO3a, phospho-FoxO3a, total Akt, phospho-Akt, Mcl-1, or actin (all Cell Signaling).
RT-PCR and qPCR RNA was prepared using TRIZOL (Invitrogen, Carlsbad, CA) and cDNA using the Lentivirus-containing shRNA infection. 
Results

CD28 signaling induced by DC or other MM cells prevents myeloma cell death.
We have previously reported that antibody-mediated CD28 activation inhibits MM apoptosis; however, this is unlikely to completely recapitulate authentic MM-stroma interactions. Since DC express CD80/CD86 and are pro-survival in the BM niche, we examined CD28's role in this MM-DC interaction. MM.1S myeloma cells were cocultured with human monocyte-derived DC (MoDC) + melphalan + CD28 blocking antibody ( Figure 1A ). Melphalan was chosen because high-dose melphalan plus autologous stem cell rescue is a therapeutic mainstay for many patients, and thus resistance is predicted to be a main cause of treatment failure. In media alone, MM survival was not significantly different with MoDC or α CD28. Melphalan significantly reduced MM survival, but co-culture with MoDC almost completely prevented MM apoptosis. However, CD28 blockade almost completely reversed this protection. On the DC side, we predicted that CTLA4-Ig (consisting of the CTLA4 extracellular domain fused to human IgG Fc) would sensitize MM cells to chemotherapy as it binds to CD80/CD86 and blocks CD28 engagement. Indeed, while melphalan significantly decreased MM survival that was rescued with MoDC, CTLA4-Ig completely abrogated this protection ( Figure 1B) . We observed a similar dependence upon CD28 signaling for survival in U266, RPMI8226, and KMS11 myeloma lines ( Figure 1C-E) .These data suggest that even in the molecularly complex MM-DC cellular interactions, CD28 delivers the predominant pro-survival signal.
Since many myelomas expressing CD28 also co-express CD86 27, 31 (Supplemental Figure 1) , we asked if cis interactions between myeloma cells are also 1 3 providing a pro-survival signal. Although melphalan's ability to kill MM cultured alone ( Figures 1A-1E , right black bars) suggest that a cis CD28:CD86 interaction between MM cells is not as potently pro-survival as the trans CD28:CD80/CD86 interaction between MM and DC, a <50% CD28 knockdown (Supplemental Figure 2) in a stromally independent MM cell line still leads to >30% death in 96 hours ( Figure 1F ). The same effect also occurs in other MM lines, including MM.1S (unpublished observation, CMB and LHB). Consistent with this death induction, we were unable to generate stable CD28 knockdowns in MM (data not shown). We further examined this in MM.1S cultured in full serum or under stress in low serum + CTLA4-Ig. Consistent with Figure   1D , myeloma survival was modestly but significantly decreased with CTLA4-Ig in full serum, but was markedly decreased in low serum ( Figure 1G ), revealing that the CD28-CD86 MM-MM cis interaction contributes to basal survival and is essential under stress.
CD28 signaling blockade in vivo sensitizes a murine myeloma model to chemotherapy.
The preceding data suggest that despite the complex nature of MM-stroma interactions, CD28 is a key mediator in MM survival in vitro. To examine the potential in vivo role for CD28:CD80/CD86, we used the immunocompetent, endogenously arising Vk*MYC murine myeloma model 37 . Vk*MYC mice develop an indolent PC dyscrasia closely mimicking human MM with elevated immunoglobulin levels and M spike 37 . Mice with tumor burden (measured by total serum IgG, Figure 2A ) have elevated cell numbers expressing PC/MM marker CD138 and coexpressing CD28 ( Figure 2B ).
Isolated CD138 + cells were cultured + serum + CD28 activating antibody to examine CD28's potential pro-survival role ( Figure 2C ). In the full-serum control, Vk*MYC cells To examine CD28's role in vivo, we treated diseased Vk*MYC mice (Figure 2A) with PBS, melphalan, CTLA4-Ig, or melphalan/CTLA4-Ig. Since melphalan alone effectively reduces tumor burden in this model 
CD28 pro-survival signaling is dependent on PI3K and Akt.
The previous data suggest CD28 signaling is critical for MM survival in vitro and in vivo. However, the specific signaling pathway downstream of CD28 in MM is almost completely uncharacterized. We and others have previously shown in MM that PI3K is phosphorylated upon CD28 engagement 20 , consistent with T cell CD28 signaling 32, 33 .
Moreover, generalized PI3K/Akt signaling has been implicated as a pro-survival pathway for MM 39 , prompting us to examine PI3K/Akt signaling downstream of CD28.
For signaling assays, serum-free conditions were used as a death signal to reduce the influence of serum factors that may also signal via PI3K/Akt, such as IGF-1 40 . By western blot ( Figure 3A ) and intracellular staining ( Figure 3B ), we confirmed that CD28 activation increases phospho-Akt levels, which is abrogated in a dose-dependent fashion by the PI3K inhibitor LY294002 or the Akt inhibitor iAkt II ( Figure 3A) . We evaluated PI3K's role downstream of CD28 ( Figure 3C and Supplemental Figure 4 ) and found that in full serum, the 2 μM inhibitor dose had no effect on MM viability, and the 5 μM dose reduced viability 11.6%. In serum-free conditions without PI3K inhibition, viability was significantly reduced, and this was largely reversed with CD28 activation.
PI3K inhibition in serum-free conditions does not significantly reduce survival further 1 6 compared to no treatment. However, PI3K inhibition prevented CD28-mediated prosurvival signaling in a dose-dependent fashion, suggesting PI3K is critical for this pathway. To examine Akt's functional role, MM.1S were cultured with iAkt II (0.5-1.0 µM) + CD28 activation + serum ( Figure 3D ). Although there was significant survival reduction with Akt inhibition in full serum, the impact of Akt inhibition was substantially greater in serum-free conditions, and CD28's pro-survival effect was inhibited in a dosedependent fashion. Together, these data suggest CD28-mediated survival activation is dependent on downstream PI3K/Akt signaling.
FoxO3a is downstream of CD28 and regulates myeloma cell survival.
There are many potential Akt targets that could play a role in myeloma survival.
We examined the effects of transcription factor FoxO3a because of its known role in regulating apoptotic molecule expression 41, 42 and its inhibition by Akt 43 . Activated Akt induces FoxO3a phosphorylation-causing FoxO3a nuclear export and degradation 44 .
Unphosphorylated FoxO3a translocates into the nucleus and acts as a tumor suppressor, mainly through transcriptional upregulation of pro-apoptotic proteins Bim and Puma and down-regulation of inhibitory caspase 8 mimic FLIP 41, 42, [45] [46] [47] . CD28
signaling inactivates FoxO3a by increasing phospho-FoxO3a levels ( Figure 4A ). Since unphosphorylated FoxO3a is an apoptosis inducer in other systems 41, 46, 48 , we predicted FoxO3a knockdown (80% by mRNA, 65% by protein, Figure 4B -C) would blunt death induced by blocking MM-MM CD28:CD86 interactions with CTLA4-Ig. In serum-free conditions, scramble and FoxO3a siRNA-treated cells were similarly viable ( Figure 4C ).
Scramble siRNA-treated cell viability was reduced to <10% with CTLA4-Ig (similar to Figure 1A ). However, CD28 blockade-induced death is significantly less with FoxO3a knockdown ( Figure 4D ), indicating that FoxO3a is an important survival/apoptosis mediator downstream of CD28.
Bim is downstream of CD28 signaling and regulates myeloma cell survival or apoptosis.
Our preceding data suggest that apoptotic proteins are downstream of FoxO3a.
One likely candidate is the pro-apoptotic protein Bim, which has been implicated in CAM-DR 21 . We predicted CD28-mediated Bim regulation would be transcriptional via These data are correlative, so to test Bim's functional role in the CD28 survival pathway, we silenced Bim (>90%, Figure 5E ) and found that scramble siRNA-treated MM.1S cultured in serum-free conditions are 45% alive. Bim siRNA-treated cells had slightly (but significantly) improved survival. CTLA4-Ig reduced scramble-treated cell viability to <10%, but Bim knockdown significantly ameliorated death due to CD28 blockade ( Figure 5F ), suggesting that CD28-mediated Bim regulation is important for survival. However, survival is not completely restored, suggesting other factors downstream of CD28 may play a role in survival.
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Discussion
Myeloma survival depends upon interactions between the MM cell and the stromal/cellular compartment of the BM, similar to normal BMPC. We have reported that CD28 signaling is essential for BMPC survival 26 and transduces a pro-survival signal directly to MM cells 20 . Here, we characterize the specific molecules of CD28's signaling pathway and identify PI3K/Akt as necessary components ( Figure 6 ). We have shown that PI3K/Akt inhibition abrogated CD28's pro-survival signal in a dosedependent fashion. While it is formally possible that this was due to off-target inhibitor effects, the observation that CD28 induces Akt phosphorylation supports the conclusion that CD28 is activating a PI3K Akt signal. Since FoxO3a is an Akt target, and upregulated Bim in MM cells, although specific receptors delivering this signal were not determined 51 . Our data suggest that one such receptor in myeloma is CD28.
Treatment of MM in vitro with CTLA4-Ig to block tonic CD28 signaling inhibited this PI3K/Akt/FoxO3a/Bim pathway, and sensitized cells to serum starvation and melphalan.
This CD28 dependence was recapitulated in vivo with CTLA4-Ig/melphalan. In this work, we did not specifically characterize which cells in the BM microenvironment provide the ligands. Our prior work 14, 20 and experiments in Figure 1 suggest that DC and MM cells themselves are important sources of CD80 and/or CD86. However, macrophages 19 and eosinophils 52 are also present in the MM microenvironment and express CD80/CD86. Non-hematopoietic stromal cells also express CD80/CD86 [53] [54] [55] , although this has not been characterized in the myeloma microenvironment. Regardless of ligand source, these experiments suggest blocking CD28:CD80/CD86 is sufficient to sensitize MM cells to chemotherapy. Importantly, the melphalan dose used was subtherapeutic, suggesting that removing the CD28 signal sensitizes MM cells to a dose of melphalan to which they are usually resistant. Since melphalan resistance is clinically correlated with shorter survival times and worse outcomes 56 , CD28 blockade may represent a novel approach to re-sensitize resistant cells to treatment. We have recently shown CD28 activation also conferred resistance to dexamethasone, arsenic trioxide, and bortezomib 14 . Therefore, blocking CD28:CD80/CD86 is likely to re-sensitize MM cells to a range of chemotherapies. Importantly, CTLA4-Ig (abatacept) is already FDAapproved for rheumatoid arthritis and psoriasis 57 and could be readily translated for MM treatment.
For
Our work suggests that CD28-mediated pro-survival signaling is dependent upon FoxO3a regulation and inhibition of Bim expression. Interestingly, although 65% FoxO3a knockdown was sufficient to prevent CD28-blockade induced death, 90% Bim knockdown did not completely restore survival. This suggests that FoxO3a is essential for CD28's pro-survival signal, but Bim may not be the only apoptotic mediator downstream of CD28-induced FoxO3a inactivation. This is unsurprising given that FoxO3a regulates other apoptotic molecules such as Puma 58 and FLIP 42 that may be affected by FoxO3a silencing. Nevertheless, the fact that Bim knockdown increased cell survival 3-fold suggests it is an important component of CD28 pro-survival signaling.
Intriguingly, CD28 and CD86 co-expression appear to be necessary but not sufficient to promote MM survival. This is somewhat unexpected given that CD28 + primary myelomas are also CD86 +27 and CD86 expression is a poor prognostic indicator, suggesting this cis interaction is important for the biology of primary MM and not just cell lines. DC possibly deliver qualitatively different trans signal because they express increased adhesion molecules and both ligands. We would therefore speculate that the cis interaction could be central to MM cell survival outside of the BM and development of extramedullary disease.
In summary, we propose that CD28-mediated PI3K/Akt signaling is critical for Whole bone marrow from Vk*MYC mice was isolated and percent myeloma cells were 
